Navigation Links
H1N1 Influenza "Swine Flu" Peptide Vaccine Now Available For Testing Worldwide
Date:5/1/2009

Replikins, Ltd. has announced that it has produced a synthetic H1N1 swine flu vaccine, Replikins PanFlu™, which is ready for testing worldwide. The company has developed the vaccine based on the same Replikins peptide technology which provided the surprise advance warning one year ago that the current H1N1 outbreak/pandemic was on its way.

London, UK (PRWEB) May 1, 2009 -- Replikins, Ltd. has announced that it has produced a synthetic H1N1 swine flu vaccine, Replikins PanFlu™, which is ready for testing worldwide.

The company has developed the vaccine based on the same Replikins peptide technology which provided the surprise advance warning one year ago that the current H1N1 outbreak/pandemic was on its way.

In April 2008, Replikins, Ltd announced the likelihood of H1N1 outbreaks based on the company's patented Replikin Count™ genomics technology, which examines specific regions in virus genes that have been linked with past epidemics. The company's chairman, Dr. Samuel Bogoch, found that the regions have been conserved for decades. In H1N1 last year the company detected the highest concentrations of these specific regions ever seen, except for those from the 1918 flu pandemic which killed tens of millions of people. To date, no other method has been able to predict whether and what strain of a given organism will threaten a human or animal population.

The company is producing the new product after achieving test results against two previous viral outbreaks: the lethal Taura virus with shrimp populations and the avian flu (H5N1) with chicken populations. The company's closely related Replikins vaccine against avian flu, produced in a 7 day period, was recently tested at the University of Georgia and shown to block H5N1 virus entry, replication, and excretion in chickens (paper submitted for publication).

Institutions requesting Replikins' H1N1 vaccine for testing should contact: jmckenney @ replikins.com

http://www.replikins.com

# # #

Read the full story at http://www.prweb.com/releases/2009/05/prweb2384744.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Germgards Ultra-Fast Hand Hygiene Solution Protects Against Deadly MRSA, C difficile, and Influenza Virus
2. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
3. Hoviones TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza
4. NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
5. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
6. Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
7. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
8. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
9. Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
10. Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1
11. DaVita Launches Flu Fighter Program in Support of National Influenza Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 19, 2017  ArmaGen, Inc., today announced ... Ph.D., as chief executive officer, as well as ... brings to ArmaGen more than 17 years of ... development of biotherapeutics and pharmaceuticals. ... diverse experience and skillset necessary to lead ArmaGen ...
(Date:1/19/2017)... ... 2017 , ... FireflySci Inc. is a go-getter type of company that continues ... to two main factors. The first is the amazing customer service that the ... products all around the world. , 2016 was a tremendous sales year for FFS ...
(Date:1/19/2017)... -- Acupath Laboratories, Inc., a leading provider of sub-specialized ... Committee that will guide the company,s vision and strategy ... , a 15-year veteran of the anatomic pathology industry, ... Chief Sales Officer .  Prior to joining Acupath ... leadership roles at several leading lab industry organizations including, ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, will feature ... compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, ... . Napabucasin is an orally-administered ... targeting STAT3. i Cancer stem cells (CSCs) possess ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec 16, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... The biometric ... grow at a CAGR of 14.06% from 2016 to 2021. The ... is projected to reach 854.8 Million by 2021. The growth of ...
(Date:12/15/2016)... Germany , December 15, 2016 ... announced an agreement with NuData Security, an award-winning ... partnership will enable clients to focus on good customer experience, ... protection regulation. ... In order to provide a one-stop fraud prevention suite, ...
(Date:12/15/2016)... -- ... Research and Markets has announced the addition of the "Global Military ... report forecasts the global military biometrics market to grow at a CAGR ... been prepared based on an in-depth market analysis with inputs from industry ... the coming years. The report also includes a discussion of the key ...
Breaking Biology News(10 mins):